

Iran (Islamic Republic of)

Eastern Mediterranean Region




I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
Number of active foci	159		Plasmodium species: <i>P. falciparum</i> (2%), <i>P. vivax</i> (98%)
Number of people living within active foci	456,000	1	Major anopheles species: <i>An. stephensi</i> , <i>An. culicifacies</i> , <i>An. fluviatilis</i> , <i>An. superpictus</i>
Malaria-free (0 cases)	79,800,000	99	Reported indigenous confirmed cases (health facility): 81
Total	80,280,000		Confirmed cases at community level: -
			Reported indigenous deaths: 0


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2005	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2005	First-line treatment of <i>P. falciparum</i>	AS+SP+PQ	2010					
IRS	IRS is recommended	Yes	1949	Treatment failure of <i>P. falciparum</i>	AL; AL+PQ	2010					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; QN	-					
Larval control	Use of larval control recommended	Yes	1949	Treatment of <i>P. vivax</i>	CQ+PQ(14d & 8w)	-					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.75 mg/Kg (8 weeks)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	1949	Type of RDT used		P.f + all species (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	1949								
Treatment	ACT is free of charge for all ages in public sector	Yes	2005	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	1949	AS+SP	2010-2012	0	0	1	28 days	6	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	1949	CQ	2010-2010	0	0	0	28 days	1	<i>P. vivax</i>
	G6PD test is a requirement before treatment with primaquine	No	1949	Insecticide resistance tests (mosquito mortality, %)							
	Directly observed treatment with primaquine is undertaken	Yes	1949	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
System for monitoring adverse reactions to antimalarials exists	Yes	1949	Carbamates	2010-2015	0.8	0.9	1	10	<i>An. culicifacies s.l.</i> , <i>An. stephensi</i> , +other		
Surveillance	ACD for case investigation (reactive)	Yes	1949	Organochlorines	2010-2016	0.2	0.6	1	11	<i>An. culicifacies s.l.</i> , <i>An. stephensi</i> , +other	
	ACD of febrile cases at community level (pro-active)	Yes	1949	Organophosphates	2010-2015	0.8	1	1	11	<i>An. culicifacies s.l.</i> , <i>An. stephensi</i> , +other	
	Mass screening is undertaken	No	-	Pyrethroids	2010-2015	0.5	0.9	1	14	<i>An. culicifacies s.l.</i> , <i>An. stephensi</i> , +other	
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	Yes	2010								
Case reporting from private sector is mandatory	Yes	1949									





III. Financing



Government expenditure by intervention in 2016



IV. Coverage



V. Impact

